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Abstract 18 
Study question:Do the chemotherapeutic regimens of ABVD (adriamycin, 19 
bleomycin, vinblastine and dacarbazine), or OEPA-COPDAC (combined vincristine, 20 
etoposide, prednisone, doxorubicin (OEPA) and cyclophosphamide, vincristine, 21 
prednisone, dacarbazine (COPDAC)) used to treat Hodgkin lymphoma, affect the 22 
density, morphology and in vitro developmental potential of human ovarian follicles?  23 
 24 
Summary answer: Ovarian tissue from women treated with ABVD contained a 25 
higher density of non-growing follicles/mm3 and increased numbers of multi-ovular 26 
follicles, but showed reduced in vitro growth compared with patients with lymphoma 27 
who had not received chemotherapy, patients treated with OEPA-COPDAC, age-28 
matched healthy women and age-related model-predicted values.  29 
 30 
What is known already: Chemotherapy regimens can cause a loss of follicles within 31 
the ovary that depends on the drugs given. Early stage Hodgkin lymphoma is 32 
commonly treated by ABVD, a non-alkylating regimen which apparently has ovarian 33 
sparing qualities,thus it is important to investigate the histological appearance and 34 
distribution of follicles within ABVD-treated ovarian tissue. 35 
 36 
Study design, size, duration:Thirteenovarian biopsies were obtained from Hodgkin 37 
lymphoma patients (6 adolescents and 7 adults)and one biopsy from a non-Hodgkin 38 
lymphoma patient.TwoHodgkin lymphoma patients and the non-Hodgkin lymphoma 39 
patient had received no treatment prior to biopsy collection. The remaining 11 40 
Hodgkin lymphoma patients received one of two regimens; ABVD or OEPA-41 
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COPDAC. Tissue was analysed histologically andcompared to biopsies from healthy 42 
women, and in a sub-group of patients, tissue wascultured for 6 days in vitro. 43 
 44 
Participants/materials, setting, methods:Ovarian biopsies were obtained from 45 
patients undergoing ovarian cryopreservation for fertility preservation, and from 46 
healthy women at the time of Caesarian section (‘obstetric tissue’). Follicle number 47 
and maturity were evaluated in sections of ovarian cortical tissue, and compared to 48 
an age-related model of mean follicle density and to age-matched contemporaneous 49 
biopsies. The developmental potential of follicles was investigated after 6 days tissue 50 
culture. 51 
 52 
Main results and the role of chance: A total of 6877 follicles was analysed.ABVD-53 
treated tissue contained a higher density of non-growing follicles/mm3 (230±17) 54 
(mean±SEM) than untreated (110±54), OEPA-COPDAC-treated (50±27 and 55 
obstetric tissue (20±4)(P< 0.01),with follicle density 9-21 standard deviations higher 56 
than predicted by an age-related model. Bi-ovular and binucleated non-growing 57 
follicles occurred frequently in ABVD-treated and in adolescent untreated tissue but 58 
were not observed in OEPA-COPDAC-treated or obstetric tissue, although OEPA-59 
COPDAC-treated tissue contained a high proportion of morphologically abnormal 60 
oocytes (52% versus 23% in untreated, 22% in ABVD-treated and 25% in obstetric 61 
tissue; P< 0.001). Activation of follicle growth in vitrooccurred in all groups, but in 62 
ABVD-treated samples there was very limited development to the secondary stage, 63 
whilst in untreated samples from lymphoma patients growth was similar to that 64 
observed in obstetric tissue  (untreated; P< 0.01 versus ABVD-treated, ns versus 65 
obstetric).  66 
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 67 
Large scale data: N/A 68 
 69 
Limitations, reasons for caution: Although a large number of follicles were 70 
analysed, these data were derived from a small number of biopsies. The 71 
mechanisms underpinning these observations have yet to be determined and it is 72 
unclear how they relate to future fertility.  73 
 74 
Wider implications of the findings: This study confirmsthat the numberof non-75 
growing follicles is not depleted following ABVD treatment, consistent with clinical 76 
data that female fertility is preserved. Our findings demonstrate that immature follicle 77 
density can increase as well as decrease following at least one chemotherapy 78 
treatment. This is the first report of morphological and follicle developmental 79 
similarities between ABVD-treated tissue and the immature human ovary. Further 80 
experiments will investigate the basis for the marked increase in follicle density in 81 
ABVD-treated tissue.  82 
 83 
Study Funding/competing interests: Funded by UK Medical Research Council 84 
Grants G0901839 and MR/L00299X/1. The authors have no competing interests. 85 
Keywords: ovary/ follicle/ lymphoma/ 86 
ABVD/oocyte/primordial/chemotherapy/regeneration/ modelling 87 
 88 
 89 
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Introduction 91 
 92 
The number of follicles in the ovary decreases progressively with age. Treatments 93 
such as some chemotherapy agents can accelerate this loss leading to premature 94 
ovarian insufficiency (POI) with loss of fertility and estrogen deficiency in female 95 
survivors of cancer (Morgan et al., 2012). The likely range of mechanisms of drug-96 
induced ovarian damage hasyet to be fully characterised but includes direct damage 97 
to growing and non-growing follicles, and loss of growing follicles may lead to the 98 
recruitment of dormant follicles to the growing phase which in turn are lost, thus 99 
accelerating the depletionof the non-growing pool, ie the ovarian reserve(Meirow et 100 
al., 2010; Morgan et al., 2012; Kalich-Philosoph et al., 2013).  101 
Since the mid-1970s the standard first line treatment for early stage Hodgkin 102 
lymphoma (HL)in many countries has been adriamycin, bleomycin, vinblastine and 103 
dacarbazine (ABVD) (Bonadonna and Santoro, 1982; Meirow and Nugent, 2001; 104 
Meyer et al., 2012). Early stage HL patients receiving ABVD based treatment where 105 
involved field radiotherapy does not include the ovarieshave a good reproductive 106 
prognosis for both fertility and risk of POI (Hodgson et al., 2007,Swerdlow et al., 107 
2014, ).In contrast advanced stage HL patients treated with a drug regimen 108 
containing one or more alkylating agents and involved field radiotherapy have a 109 
higher prevalence of POI (Behringer et al., 2005), and should therefore be 110 
considered for fertility preservation strategies before commencing treatment 111 
(Anderson et al., 2015). 112 
The purpose of this study was to examinemicroscopically, ovarian tissue from 113 
patients with lymphoma exposed to ABVD chemotherapy and compare this with 114 
samples exposed to the combined alkylating chemotherapeutic regime (OEPA-115 
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COPDAC)(combined vincristine, etoposide, prednisone, doxorubicin (OEPA) and 116 
cyclophosphamide, vincristine, prednisone, dacarbazine (COPDAC), with samples 117 
not previously exposed to chemotherapy and with further samples from healthy 118 
women to determine whether follicle density, morphology and in vitro developmental 119 
potential were affected by these chemotherapeutic interventions. Comparing follicle 120 
densities across treatments requires identification of changes to non growing 121 
follicle(NGF) cortical densities in comparison with those predicted by age related 122 
models (Kelsey & Wallace., 2012; Kelsey et al., 2013).In this study we used a 123 
recently reported validated age-related model of mean follicle density(MFD) in the 124 
ovarian cortex (McLaughlin et al., 2015), to compare observations of MFD in tissue 125 
obtained after different chemotherapy regimens. 126 
 127 
Materials and Methods 128 
Patient Selection 129 
Diagnosis, patient age, chemotherapeutic regimen, anti-Müllerian hormone (AMH) 130 
concentrationsand time between completion of treatment and biopsy collection are 131 
detailed in Table 1.  132 
Ovarian Cortical Tissue  133 
Ovarian biopsies were obtained laparoscopically from 6 adolescentsand 7 adults 134 
diagnosed with Hodgkin lymphoma and 1 adult diagnosed with non-Hodgkin 135 
lymphoma. All patients were undergoing removal of ovarian cortex for fertility 136 
cryopreservation either prior to chemotherapy or following relapse of previously 137 
treated illness. Protocols for tissue donation for research had Ethical Committee 138 
approval fromSouth East Scotland Research Ethics Committee (ref 06/S1103/26) 139 
and all patients gave informed consent in writing. The mean patient age was 140 
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20.2±1.5 years (mean ±SEM) with a range of 12.0 – 30.0 years. For analyses 141 
patients were divided into 3 groups: those treated with ABVD (aged 16 – 29 years, n 142 
= 8), those treated with OEPA-COPDAC (aged 14 – 16 years, n = 3) and untreated 143 
patients or controls (aged 12 – 30 years, n = 3). Data were compared with results 144 
obtained from contemporaneous ovarian biopsies obtained from adult women 145 
undergoing elective Caesarean section (age range 23 – 39 years, n = 12) prepared 146 
and processed in an identical manner, also obtained with written informed consent 147 
and Ethical committee approval (ref 10/S1101/24). 148 
 149 
Tissue preparation and processing 150 
Fresh ovarian biopsies(ranging in size from 8x5mm and 6x4mm all with variable 151 
thickness)were transported to the laboratory in holding medium (Leibovitz medium, 152 
Gibco; Life Technologies, Paisley, Renfrewshire, UK supplemented with 2mM 153 
sodium pyruvate, 2mM L-glutamine, 3mg/ml human serum albumin, 75mg/ml 154 
penicillin G and 50mg/ml streptomycin; all chemicals from Sigma-Aldrich, Poole, 155 
UK). Tissue was transferred into fresh pre-warmed (37oC) holding medium and 156 
examined under a dissecting light microscope. A scalpel and fine forceps were used 157 
to remove any damaged or haemorrhagic areas as well as any tissue adhering to the 158 
underside of the biopsies to leave only intact cortex in place. Using a scalpel the 159 
tissue was divided into fragments of approximately 4 x 2 x 0.5 mm; the number of 160 
fragments varied between biopsies. Fragments were fixed in 10% neutral buffered 161 
formalin (NBF) for 48h then processed and prepared for staining and microscopic 162 
evaluation as previously described (McLaughlin et al., 2014). 163 
Thawing of cryopreserved tissue 164 
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Two of the biopsies were cryopreserved by slow freezing (Gosden et al., 1994) and 165 
were donated for research at the patients’ request. Tissue was thawed as described 166 
previously (Anderson et al., 2014), inspected, divided into fragments, fixed and 167 
processed for staining and analysis as described above. 168 
Assessment of mean follicle density in ovarian biopsies  169 
Each histological section of every tissue fragment was examined under light 170 
microscopy. Follicles were categorised according to their stage of development as 171 
previously described (Telfer et al., 2008; McLaughlin et al., 2014). To avoid over-172 
counting, only follicles containing the nucleolus were assessed. The volume of tissue 173 
analysed per patient was calculated as described previously (Lass et al., 1997; 174 
Anderson et al., 2014). Briefly, tissue volume was calculated as the sum of the area 175 
in mm2 of all tissue sections analyzed per patient, multiplied by 0.006 mm (the 176 
thickness of the sections) to give a value in mm3. The area of each section was 177 
measured andmean follicle density was determined by dividing the total number of 178 
follicles per patient by the volume of tissue analyzed in mm3 (Anderson et al., 2014). 179 
 180 
Evaluation of histology 181 
Evaluation of the tissue sections was performed blinded to the treatment groups. 182 
Follicles in freshly fixed and cultured tissue pieces were categorised by 183 
developmental stage based on morphology as previously described (McLaughlin et 184 
al., 2014).Follicle morphological normality was determined by an assessment of the 185 
appearance of the oocyte and surrounding cells using the cross-section containing 186 
the nucleolus as described previously (McLaughlin and Telfer, 2010, McLaughlin et 187 
al., 2014). The presence of bi-ovular and binucleate follicles was also noted. 188 
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The spatial relationship between follicles was also assessed and classified as (1) 189 
single i.e. no follicles within 15 µm of the follicle being evaluated, (2) in close 190 
proximity i.e. at least one other follicle occurring within 15µm of the follicle being 191 
evaluated or (3) direct contact i.e. where 2 or more follicles appeared to share the 192 
same basal lamina or the basal laminae of 2 or more follicles abutted. Follicles were 193 
classified as occurring in clusters if 5 or more follicles were found in direct contact or 194 
close proximity. The presence of naked oocytes with few or no surrounding cells was 195 
also noted.  196 
 197 
Fragment culture 198 
Prior to fixation a number of tissue fragments were selected at random from a sub-199 
section of the ABVD-treated patients (n = 4; age range 23 - 29 years), 1 OEPA-200 
COPDAC-treated patient (16 years), 2 untreated controls (15 years and 30 years) 201 
and from obstetric patients (n = 10; age range 23 – 36 years). Between 2 and 6 202 
fragments were obtained for each patient, prepared for culture and incubated for 6 203 
days then processed for histological evaluation as previously described (McLaughlin 204 
et al., 2014). 205 
 206 
Immunohistochemistry  207 
A number of ABVD-treated, OEPA-COPDAC-treated and control tissue fragments 208 
fixed in NBF and embedded in paraffin as described previously (McLaughlin et al., 209 
2014) were selected at random and cut in 6µm sections and mounted on charged 210 
slides to investigate the expression of the germline marker proteinDEAD box 211 
polypeptide 4 (DDX4). Antigen retrieval was performed using 0.01M sodium citrate 212 
and endogenous peroxidase activity quenched by 3% hydrogen peroxide in 213 
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methanol. Tissue sections were incubated in anti-DDX4/MVH ab13840 polyclonal 214 
primary antibody (Abcam, Cambridge, UK) overnight at 4oC. Negative controls were 215 
established by replacing the primary antibody with goat serum. On completion of 216 
incubation, sections were washed and probed with anti-rabbit secondary antibody 217 
labelled with horseradish peroxidase for 30 mins (ABC-Elite Rabbit IgG, Vectastain 218 
Elite Kit, PK-6101, Vector Laboratories Ltd, Peterborough, UK). DDX4 was detected 219 
using 3, 3’-diaminobenzidine (DAB) peroxidase substrate kit (Vector Laboratories 220 
Ltd, Peterborough, UK). Structures were positively identified as germ cells when 221 
brown staining was observed within a cell.   222 
 223 
Statistical analysis 224 
Observed mean follicle densities were compared to predicted mean follicle densities 225 
using an age-related model of mean follicle density in the cortex of the human ovary 226 
(McLaughlin et al., 2015). Chi-Square Goodness-of-Fit analysis was used to test the 227 
null hypotheses that the observations matched predicted MFD. Pearson's product-228 
moment correlation coefficients were also calculated tocompare datato the line of 229 
identity where predictions exactly match observations. Due to the need for high 230 
confidence in the significance of any observed differences between predicted and 231 
observed densities, statistical significance was set at the 99% level throughout. 232 
Bland-Altman analysis was used to estimate the number of standard deviations away 233 
from agreement between observations and predictions using the limits of agreement 234 
reported in McLaughlin et al. (2015). 235 
 236 
Results  237 
Follicle density  238 
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The number of follicles and their developmental stage were determined by 239 
examining fresh and post-thawed fixed ovarian tissue from 14 previously treated and 240 
untreated lymphoma patients and an age-matched group of 12 obstetric patients; a 241 
total of 6877 follicles were examined. The total number of follicles counted in each 242 
group and the volume of tissue analysed are shown in Table 2. Ages and MFDs for 243 
the three groups of lymphoma patients are shown in Fig. 1A, together with age-244 
related predictions taken from McLaughlin et al., (2015). For the three patients 245 
whoreceived no chemotherapy we have insufficient evidence to reject the null 246 
hypothesis that the observed values for MFD are a perfect fit with predicted values 247 
taken from the age-related model derived from data from other subjects receiving no 248 
chemotherapy: Chi-square p-value = 0.07; Pearson's product-moment correlation 249 
coefficient = 0.999 (p< 0.01, Fig. 1B) with the observations within 1.25 standard 250 
deviations of agreement between observed and predicted values (Fig. 1C). 251 
Thethreepatients who received OEPA-COPDAC chemotherapy had significantly 252 
lowerobserved MFD than predicted: Chi-square p-value < 0.01; Pearson's product-253 
moment correlation coefficient = -0.399 (p = 0.74, Fig. 1B) with the observations 254 
between 0 and 11 standard deviations lower than the predictions (Fig. 1C).  255 
However,the eight patients who had received ABVD chemotherapy had higher 256 
numbers of non-growing follicles (160-303/mm3) compared with samples from 257 
healthy women (8-46/mm3) (Table 2). The ABVD group had significantly 258 
higherobserved than predicted MFD: Chi-square p-value < 0.001; Pearson's product-259 
moment correlation coefficient = 1.57 (p = 0.71, Fig. 1B) with observations between 260 
9 and 21 standard deviations higher than the predictions (Fig.1C).  261 
 262 
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Time elapsed between completion of chemotherapy regimen and biopsy ranged from 263 
1 to 36 months, with six of the eight ABVD-treated patients having tissue collected 264 
within 6 weeks and all OEPA-COPDAC patients undergoing biopsy within 9 months 265 
of treatment. No correlation was foundbetween the time interval and the MDF 266 
observed in tissue treated with either regimen: the marked increase in MFD in 267 
ABVD-treated tissues was observed in biopsies taken within 4 weeks of 268 
chemotherapy completion and was also present in samples taken up to 36 months 269 
after treatment, although the small sample size at the later treatment times does not 270 
allow for time after treatment to be robustly tested. The OEPA-COPDAC tissue from 271 
two out of three patients showed follicle numbers below that predicted at 6-9 months 272 
post treatment.Biopsy tissue was only available from each patient at one time point 273 
therefore it was not possible to investigate by histological means whether 274 
deterioration or recovery of NGF density occurred over time.    275 
 276 
Follicle categorisation  277 
The majority of all follicles observed in fixed tissue were non-growing irrespective of 278 
illness, treatment or age (Fig. 2A).  However ABVD-treated tissue contained a 279 
significantly smaller percentage of growing follicles (3.0%) compared to untreated, 280 
OEPA-COPDAC-treated and obstetric patients (15.6%, 21.4% and 18.0% 281 
respectively; p< 0.001) (Fig. 2A). 282 
Analysis of oocyte appearance showed that in biopsies collected from untreated, 283 
ABVD-treated and obstetric patients, morphological normality was high with >74% of 284 
oocytes appearing normal. In contrast less than half of the oocytes in follicles 285 
observed in OEPA-COPDAC-treated tissue met the criteria for normality (41.9% in 286 
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OEPA-COPDAC compared to 76.8% in untreated; 78.4% in ABVD-treated and 287 
74.2% in obstetric samples; p< 0.001) (Fig. 2C and D).   288 
 289 
Follicle development in cultured tissue 290 
To investigate the in vitro developmental potential of chemotherapy-exposed 291 
follicles, tissue fragments from a subset of patients representing each group were 292 
cultured for 6 days. It was not possible to culture fragments from everypatient due to 293 
the limited amount available. A total of 89, 614 and 274 follicles were analysed in 294 
cultured tissue obtained from untreated (n = 2), ABVD-treated (n = 4) and obstetric 295 
patients (n = 10) respectively. Analysis of cultured tissue fragments from two patients 296 
treated with OEPA-COPDAC has been omitted due to extreme follicle degeneration 297 
in both patients.  Initiation of follicle growth was observed in all of the 3 remaining 298 
groups. Post-culture the proportion of growing follicles was 19.9% in ABVD-treated 299 
tissue, 41.6% in untreated tissue and 46.3% in obstetric samples (all P< 0.001 300 
versus uncultured)(Fig. 3A). Development to the secondary stage occurred in both 301 
untreated and obstetric groups with 18% and 18.2% of follicles observed reaching 302 
this stage respectively whereas very few follicles progressed in the ABVD-treated 303 
tissue,comprisingonly 1.2% of follicles at the secondary stage after culture (Fig 3B 304 
and C). 305 
 306 
Immunohistochemical localization of DDX4 307 
Due to the high density of non-growing follicles observed in ABVD-treated tissue and 308 
the presence of clusters, bi-ovular and binucleate follicles, immunohistochemistry 309 
was performed to examine whether the germline marker DDX4 could be localized in 310 
these structures. Uncultured tissues sections from 9 patients representing all groups 311 
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were studied; the number of sections per patientwas variable due to tissue 312 
availability, and the number of follicles per section was also highly variable. Discrete 313 
positive DDX4 staining was observed in oocytes of follicles at all stages of 314 
development in all groups. DDX4 was also localised to the bi-ovular and binucleate 315 
oocytes and clusters of naked oocytes with adjacent or shared oolemmae observed 316 
in ABVD-treated tissue. No positive staining was observed in any tissue sections 317 
where the primary antibody had been omitted (Fig. 3D). 318 
 319 
Spatial distribution of follicles 320 
In all groups individual follicles and groups of follicles were distributed unevenly 321 
throughout the cortex however the pattern of distribution varied between groups with 322 
the majority of follicles occurring discretely (single follicles ≥ 15µm apart)in obstetric 323 
tissue (Fig. 4A and B).  ABVD-treated and untreated adolescent tissues 324 
appearedmarkedly different from the others examined, withsignificantly fewer 325 
discrete follicles seen and clusters of closely packed follicles (5 or more NGF ≤ 15µm 326 
apart) observed in these groups(p< 0.05; ABVD-treated and untreated versus OEPA-327 
COPDAC-treated and obstetric patients(Fig.4A and C).Bi-ovular and binucleate 328 
follicles were observedin ABVD-treated tissues and also in the 12 year old untreated 329 
patient’s tissue comprising between 8-18% of the NGF population. These structures 330 
were not observed in the other tissues examined. Follicle clusters often contained 331 
naked or partially naked oocytes, which otherwise appeared morphologically normal 332 
(Fig 4C).   333 
 334 
 335 
Discussion  336 
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Ovarian dysfunction and reduced fertility potential can be a consequence of cytotoxic 337 
therapy particularly where alkylating agents have been used, with resultant loss of 338 
the ovarian reserve (Meirow et al., 2010). In contrast women diagnosed with 339 
lymphoma and treated with the gonad-sparing regimen ABVD have a low risk of 340 
significant impairment of fertility (Hodgson et al., 2007)or of POI (Swerdlow et al., 341 
2014) and no reduction in follicle numbers have been observed (Seshadri et al., 342 
2006). The impact of chemotherapy on the ovarian reserve is evaluated indirectly by 343 
clinical parameters including amenorrhea,AMH and FSH levels (Meirow, 2000; Oktay 344 
et al., 2006; Anderson and Cameron, 2011). Post-treatment AMH levels in 345 
lymphoma patients clearly show the differential impact of ABVD and alkylating agent 346 
based regimens (Decanter et al., 2010)and AMH levels may also be reduced at the 347 
time of diagnosis (Lawrenz et al., 2012).  Although early studies showed that 348 
chemotherapy reduced the number of antral follicles in the ovary in girls treated for 349 
leukaemia (Himelstein-Braw et al., 1978),this is the most detailed quantitative 350 
analysis of the direct effect of chemotherapy treatment on density of the ovarian 351 
reserve in lymphoma patientsand the impact of the different chemotherapy regimens 352 
on morphology and in vitro developmental potential of follicles. In this study we have 353 
identified and quantified differences in the non-growing follicle population of treated 354 
and untreated lymphoma patients. The observed MFD of untreated lymphoma 355 
patients were close to the densities predicted by an age-related model indicating that 356 
the disease itself is not implicated in the variationsof the ovarian reserve observed in 357 
the chemotherapy-treated groups.  358 
Treatment regimens containing alkylating agents such as cyclophosphamide are 359 
known to lead to POI via a direct or indirect reduction in the NGF population (Oktem 360 
and Oktay, 2007; Meirow, 2000; Meirow et al., 2010).Our finding that patients treated 361 
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with the OEPA-COPDAC regimen had lower than predicted MFDs confirms and 362 
quantifies this, although the MFD in this small group varied from very low to close to 363 
average for age. Further analysis of the degree of loss is not possible without 364 
knowing pre-treatment values. In this study patients treated with OEPA-COPDAC 365 
were all teenagers (14, 15 and 16 years) at the time of tissue collection, which was 366 
6-9 months after completion of chemotherapy. Of the 3 patients included in this study 367 
treated with OEPA-COPDAC one was diagnosed with reduced ovarian reserve 368 
based on having regular menstrual cycles but undetectable AMH levels one year 369 
after completion of treatment and another was diagnosed with POI 6 years post 370 
chemotherapy.  371 
Surprisingly we found a striking and statistically highly significant increase in follicle 372 
number and MFD after ABVD chemotherapy. All eight ABVD patients had higher 373 
follicle counts (Table 2) and a markedly higher follicle density than predicted (Fig. 374 
2C).Despite the well reported variation of follicle density between and within human 375 
cortical biopsies follicles (Kohl et al., 2000; Qu et al., 2000; Poirot et al., 2002; 376 
Schmidt et al., 2003; McLaughlin et al., 2015), all ABVD-treated samples consistently 377 
showed an increase in the NGF population whereas this was not seen for any of the 378 
other groups or individual biopsies. We initially considered that thisincreasemight be 379 
attributed to a reduction in ovarian volume during treatment as all treatments would 380 
result in an initial reduction in ovarian volume because of the loss of large 381 
follicles.However, MFD is based on volume of ovarian cortex, not whole ovary and 382 
there is no evidence to support a differential effect on ovarian cortex volume by any 383 
treatment.Additionally, these samples were collected 4 weeks to 36 months after the 384 
completion of treatment with resumption of follicular growth (indicated by regular 385 
menses) in those with longer intervals and there was no apparent relationship 386 
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between increased follicle number/MFD and interval since treatment. The observed 387 
differences between ABVD MFD and control data is between 9-21 standard 388 
deviations (Figure 1C) and so a reduction in cortical volume would need to be of that 389 
order of magnitude. There are no clinical data/observations to support such a degree 390 
of shrinkage. 391 
The underlying mechanism for an increase in MFD after ABVD treatment remains to 392 
be established. An alternative explanation may be that this treatment has resulted in 393 
new oocytes/follicles being formed. Putative germline stem cells or oogonial stem 394 
cells, which may be capable of regenerating the NGF population under perturbed 395 
conditionshave been identified within the adult human ovary (White et 396 
al.,2012;Dunlop et al., 2013;Hanna and Hennebold, 2014). It is possible that the 397 
ABVD combination or specific components activate these cells to form oocytes or 398 
oocyte like structures. Recent studies have shown that mesenchymal stem cells are 399 
sensitive to bleomycin treatment (Nicolay et al., 2016) but nothing is known about 400 
how these drugs affect putative germline stem cells and other ovarian cells. 401 
We also observed that post-ABVD tissue contains follicle clusters, many containing 402 
bi-ovular and binucleate follicles, a feature more commonly associated with the 403 
prepubertal ovary (Anderson et al., 2014). Follicles with more than one oocyte are 404 
reported during fetal development and in early life in many mammalian species 405 
(Papadaki, 1978; Telfer and Gosden 1987; Silva-Santos and Seneda, 2011) but are 406 
much rarer in adults (Turkalj et al., 2013) and may be preferentially lost with 407 
abnormal follicles during childhood (Anderson et al., 2014). No bi-ovular or 408 
binucleate follicles were observed in tissue from healthy women,or following OEPA-409 
COPDAC treatment, highlighting that this difference inNGF patterning in the cortex of 410 
tissue is a result of the specific chemotherapy treatment. Furthermore, the in vitro 411 
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developmental potential of ABVD-treated tissue showed differences compared to 412 
control tissue, with limited follicle development, comparable to that from prepubertal 413 
girls(Anderson et al., 2014).We suggest that the lack of development in ABVD-414 
treated tissue may be attributed to theinhibitory effect exerted by the high density of 415 
primordial follicles present (Da Silva-Buttkus et al., 2009). Initiation of follicle growth 416 
was observed in the obstetric patient cohort supporting the findings of previous 417 
studies (Andersonet al., 2014, McLaughlin et al., 2014).  418 
In summary this study demonstrates that ABVD treatment does not diminish the 419 
ovarian reserve and may paradoxically increase it. Other significant features such as 420 
the presence of bi-ovular and binucleate oocytes and clustering are increased. In this 421 
respect, ABVD-exposed tissue is similar to that from prepubertal girls, and this 422 
similarity is also reflected in its reduced capacity for follicle development in vitro. The 423 
number of patients analysed is small and so interpretation should be cautious. 424 
However, the data presented here have highlighted a phenomenon that has not 425 
been previously reported.Further investigation is required to elucidate the 426 
mechanism by which the ovarian reserve is affected by ABVD treatment, and the 427 
consequences for later fertility and reproductive lifespan. 428 
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Legends to Figures 608 
Figure 1 (A). Observed and predicted human mean follicle density (MFD). Black 609 
dots represent model-predicted values from ages 10 through 50 years. Blue dots 610 
denote MFDs of patients that did not receive chemotherapy, green dots patients that 611 
received OEPA-COPDAC(combined vincristine, etoposide, prednisone, doxorubicin 612 
(OEPA) and cyclophosphamide, vincristine, prednisone, dacarbazine (COPDAC)) 613 
and red dots patients that receivedABVD (adriamycin, bleomycin, vinblastine and 614 
dacarbazine). All tissue was uncultured. (B) Pearson product-moment correlation. 615 
The line of identity represents the idealised confluence of observed and predicted 616 
values. Blue dots indicate observed against predicted MFD for 3 untreated patients. 617 
C) Bland-Altman Plot. The x-axis represents means (i.e. half the sum of observed 618 
and predicted MFD values); the y-axis represents the differences (i.e. predicted MFD 619 
values subtracted from observed values). The solid horizontal line shows no trend 620 
between means and differences. Blue dots denote difference from predicted MFD for 621 
untreated patients; these are between 0 and 1.25 standard deviations (i.e. between 0 622 
and 16 follicles) below the zero predicted difference. Greens dots denote difference 623 
from predicted MFD for 3 OEPA-COPDAC-treated patients’ chemotherapy protocol; 624 
these are between 1 and 11 standard deviations (i.e. between 12 and 132 follicles) 625 
below the zero predicted difference. The red dots denote difference from predicted 626 
MFD for 8 ABVD-treated patients; these are between 9 and 21 standard deviations 627 
(i.e. between 108 and 250 follicles) above the zero predicted difference. 628 
Figure 2 (A) Distribution of follicle classes (as percentage of total) in fixed ovarian 629 
tissue from either untreated,OEPA-COPDAC (combined vincristine, etoposide, 630 
prednisone, doxorubicin (OEPA) and cyclophosphamide, vincristine, prednisone, 631 
dacarbazine (COPDAC))or ABVD (adriamycin, bleomycin, vinblastine and 632 
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dacarbazine)treated girls and adults, and obstetric patients. 469, 903, 5001 and 504 633 
follicles were classified in the four groups, respectively. Blue: non-growing follicles; 634 
red: primary follicles; green: secondary follicles. (B) Photomicrographs of non-635 
growing follicles in a 22 year-old lymphoma patient treated with ABVD (main image 636 
and inset). Scale bars 30µm inset and 50µm main image.(C) Assessment of oocyte 637 
appearance within growing and non-growing follicles in fixed tissue. Fewer 638 
morphologically normal oocytes were observed in OEPA-COPDAC-treated tissue 639 
compared to other groups (p<0.001) (D) Photomicrograph of morphologically 640 
abnormal follicles in fixed tissue donated by a 16 year-old OEPA-COPDAC-treated 641 
patient (main image and inset).Scale bars 30µm inset and 50µm main image.     642 
Figure 3(A). Distribution of follicle classes (as percentage of total) in ovarian tissue 643 
cultured for 6 days from untreated (n=2) and ABVD (adriamycin, bleomycin, 644 
vinblastine and dacarbazine) treated girls and adults (n=4), and obstetric patients 645 
(n=10). Blue: non-growing follicles; red: primary follicles; green: secondary follicles. A 646 
total of 89, 614 and 274 follicles are classified in the three groups, respectively. (B) 647 
Photomicrograph of in vitro activated follicles in 23 year-old obstetric tissue. Scale 648 
bar 60µm. (C) Photomicrograph of non-growing follicles in 23 year-old ABVD-treated 649 
tissue after incubation for 6 days. Scale bar 60µm.(D) Photomicrograph showing 650 
immunohistochemical detection of DDX4 in 22 year old ABVD-treated ovarian cortex. 651 
(i) Brown staining indicating present in all structures morphologically identified as 652 
germ cells. (ii) Negative control where primary antibody was omitted. Scale bar = 653 
60µm.   654 
Figure 4 (A). Incidence (i.e.number of observations) of single (blue) and clustered 655 
(red) follicles as percentage of total in fixed ovarian tissue from untreated, OEPA-656 
COPDAC(combined vincristine, etoposide, prednisone, doxorubicin (OEPA) and 657 
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cyclophosphamide, vincristine, prednisone, dacarbazine (COPDAC)) treated, ABVD 658 
(adriamycin, bleomycin, vinblastine and dacarbazine)-treated girls and adults, and 659 
obstetric patients. (B) Photomicrograph ofnon-growing follicles(NGFs) in fixed tissue 660 
from 36 year-old obstetric tissue. Dashed blue lines indicating a distance of 661 
≤15µmbetween follicles. Scale bar 100µm. (C) Photomicrograph of non-growing 662 
follicles in fixed tissue 22 year-old ABVD-treated tissue. Purple circles indicate areas 663 
of clustered NGFs within 15µm or less of each other. Scale bar = 60µm. Inset: non-664 
growing bi-ovular follicle in ABVD-treated tissue. Scale bar 25µm in inset 665 
 666 
 667 
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Table 1. Treatment regimen (ABVD (adriamycin, bleomycin, vinblastine and 
dacarbazine), or OEPA-COPDAC (combined vincristine, etoposide, prednisone, 
doxorubicin (OEPA) and cyclophosphamide, vincristine, prednisone, 
dacarbazine (COPDAC)), anti-Müllerian hormone (AMH) level and treatment to 
biopsy time interval of patients contributing tissue. All had Hodgkin’s 
lymphoma except the final one (aged 30) who had non-Hodgkin’s lymphoma. 
 
 
Age (years) Treatment AMH (pmol/L) Treatment to Biopsy Interval 
12 none <4 n/a 
14 OEPA COPDAC not taken 9 months 
15 OEPA COPDAC not taken 6 months 
15 none <4 n/a 
16 OEPA COPDAC 10.1 6 months 
16 ABVD <4 4 weeks 
21 ABVD not taken 4 weeks 
22 ABVD <4 4 weeks 
22 ABVD <4 6 months 
23 ABVD <4 4 weeks 
23 ABVD <4 4 weeks 
25 ABVD <4 36 months 
29 ABVD not taken 6 weeks 
30 none not taken n/a 
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Table. 2. Number of follicles and non-growing follicles (NGFs) analysed in ovarian cortical 
tissue of Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and obstetric patients 
undergoing elective caesarean section (ECS). HL and NHL patients either received 
adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) or combined vincristine, 
etoposide, prednisone, doxorubicin (OEPA) and cyclophosphamide, vincristine, prednisone, 
dacarbazine (COPDAC) OEPA-COPDAC) or no treatment (Nil) prior to biopsy collection. 
 
 
 
Diagnosis Age 
(Years) 
Treatment Vol mm
3
 
Analysed 
Total No. 
follicles  
Total No. 
NGFs 
NGFs/mm
3
 
HL 12 Nil 0.92 195 187 203 
HL 15 Nil 1.7 259 194 114 
NHL 30 Nil 0.9 15 15 17 
HL 14 OEPA-
COPDAC 
1.8 19 19 10.5 
HL 15 OEPA-
COPDAC 
5.84 732 605 103 
HL 16 OEPA-
COPDAC 
2.14 152 86 40 
HL 16 ABVD 4.75 988 988 208 
HL 21 ABVD 1.53 473 464 303 
HL 22 ABVD 2.66 605 599 225 
HL 22 ABVD 1.64 444 437 266 
HL 23 ABVD 2.41 712 660 273 
HL 23 ABVD 2.6 558 506 194 
HL 25 ABVD 3.06 642 617 201 
HL 29 ABVD 3.62 579 578 160 
ECS 23 N/A 1.21 38 32 26 
ECS 24 N/A 1.45 85 73   50 
ECS 26 N/A 2.01 77 63 32 
ECS 28 N/A 2.28 67 51 22 
ECS 28 N/A 1.06 60 49 46 
ECS 31 N/A 2.72 39 38 14 
ECS 33 N/A 2.31 34 29 12.5 
ECS 33 N/A 1.98 36 26 13 
ECS 36 N/A 1.55 17 14 9 
ECS 36 N/A 2.39 15 15 6 
ECS 36 N/A 2.71 22 12 4 
ECS 39 N/A 1.32 14 11 8 
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